FindTrial
Sign In

A Randomized Controlled Trial of Transcranial Magnetic Stimulation for Parkinson’s Disease with Mild Cognitive Impairment

Mechanistic Study of Repetitive Transcranial Magnetic Stimulation Targeting the Left Dorsolateral Prefrontal Cortex and Bilateral Cerebellum in Parkinson’s Disease with Mild Cognitive Impairment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600128033
Enrollment
Unknown
Registered
2026-07-13
Start date
2026-07-15
Completion date
Unknown
Last updated
2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson’s disease with mild cognitive impairment (PD-MCI)

Interventions

DLPFC+Crus II (active+active):Repeated Transcranial Magnetic Stimulation active Stimulation+ active Stimulation
DLPFC+Crus II (active+sham):Repeated Transcranial Magnetic Stimulation active Stimulation+sham Stimulation
DLPFC+Crus II (sham+active):Repeated Transcranial Magnetic Stimulation sham Stimulation+ activeStimulation
DLPFC+Crus II (sham+sham):Repeated Transcranial Magnetic Stimulation sham Stimulation+ sham Stimulation

Sponsors

Nanjing Brain Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Diagnosis of Parkinson’s disease according to the Chinese Diagnostic Criteria for Parkinson’s Disease (2016 edition); 2.Diagnosis of PD-MCI according to the Chinese Guidelines for the Diagnosis and Treatment of Parkinson’s Disease Mild Cognitive Impairment (2020 edition); 3.Age between 45 and 80 years; 4.Hoehn and Yahr stage I–III; 5.Ability to provide written informed consent personally or via a legally authorized representative after full explanation of study procedures, risks, and benefits.

Exclusion criteria

Exclusion criteria: 1.Illiteracy; 2.Severe depression or anxiety; 3.Significant visual or hearing impairment; 4.Use of medications that may interfere with cognitive assessment (e.g., trihexyphenidyl); 5.Recent adjustment of antiparkinsonian medications; 6.Contraindications to MRI examination; 7.Contraindications to TMS treatment, including a history of epilepsy or familial epilepsy, acute cerebral hemorrhage, recent traumatic brain injury, or intracranial infection; 8.Parkinson-plus syndromes or secondary parkinsonism; 9.Severe psychiatric disorders or poor general medical condition.

Design outcomes

Primary

MeasureTime frame
Montreal Cognitive (MoCA);—

Secondary

MeasureTime frame
Attention/Working Memory Domain Z Score;Executive Function Domain Z Score;Memory function Domain Z Score;Language Domain Z Score;Visuospatial Domain Z Score;Hamilton Depression Rating Scale Score (HAMD);Movement Disorder Society-Unified Parkinson's Disease Rating Scale Score (MDS-UPDRS);Hoehn and Yahr Stage (H-Y Stage);—

Countries

China

Contacts

Public ContactWeiguo Liu

Nanjing Brain Hospital

wgliunbh@sina.com+86 139 1472 5569

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026